Qlucore, listed on Nasdaq First North, is launching a new Qlucore Insights test (Research Use Only) specifically developed for bladder cancer samples. The software-based test delivers multiple clinically relevant results from a single whole transcriptome sequencing run, helping reduce the challenges associated with manual determination of tumor stage and grade. At the same time, risk assessment can be improved through more consistent and objective analysis
Bladder cancer is the tenth most common cancer type worldwide, with an estimated 549,000 new cases and 200,000 deaths in 2018. Radical cystectomy is the standard treatment for muscle invasive bladder cancer and may also be offered to patients with very high-risk non-muscle invasive disease.
In Europe, risk assessment is based on a well-established risk scoring algorithm in which stage and grade are input parameters. By complementing these with automatic molecular subtyping, the variation that arises from manual assessment can be reduced. The test uses AI-based machine learning to classify a sample into one of five molecular subtypes according to the Lund Taxonomy, developed by a research team led by Professors Liedberg and Högström. The test also includes functionality for detecting important gene fusions.
The Qlucore Insights Bladder Cancer test is designed to integrate seamlessly into standard laboratory workflows. It is easy to implement and operate, supporting both research teams and laboratories looking to expand their molecular profiling capabilities.
This addition further expands Qlucore's portfolio of advanced testing solutions, which already includes Qlucore Insights Leukemia (AML), Qlucore Insights Lung Cancer and Qlucore Diagnostics Pediatric Leukemia BCP-ALL Test (CE IVDR).